Skip to main content

rly-2608

Generic: Zovegalisib

rly-2608: 3 clinical trials tracked.

rly-2608 evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about rly-2608, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 1 study sponsors
Clinical Trial Registry Records (3)

A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor

NCT06982521Registry updated 2026-10-05·Phase 3·RLAY
Recruiting

Primary endpoint: Progression-Free Survival (PFS) within the overall and kinase population by blinded independent central review (BICR)

InterventionalRandomizedopen540 targetStarted 2025-08Completion 2031-12243 sites · Argentina, Australia, Austria, Belgium…Relay Therapeutics, Inc.

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

NCT06789913Registry updated 2026-08-25·Phase 2·RLAY
Recruiting

Primary endpoint: Parts 1 and 2: Determination of a recommended phase 2 dose RP2D(s) for Groups 1, 2, and 3

InterventionalRandomizedopen277 targetStarted 2025-06Completion 2031-1040 sites · Australia, Belgium, France, Germany…Relay Therapeutics, Inc.

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432Registry updated 2025-09-22·Phase 1·RLAY
Recruiting

Primary endpoint: Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of RLY-2608 as a single agent

Interventionalopen930 targetStarted 2021-12Completion 2027-0437 sites · Australia, France, Italy, Spain…Relay Therapeutics, Inc.